🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma
Clinical trial register · China

Diffuse Large B Cell Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Shanghai 15 Guangzhou 14 Fuzhou 7 Changchun 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Ruijin Hospital7 Fudan University4 Hoffmann-La Roche3 Genmab3 Ting YANG2
Site location
Beijing21 Shanghai15 Guangzhou14 Fuzhou7 Changchun6
All 48 locations
Target enrolment
to

Diffuse Large B Cell Lymphoma trials in China

54 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07808827Diffuse Large B-Cell Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
282
Beijing
2026-09-24
Not yet open
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
NCT07818499Diffuse Large B-Cell Lymphoma
DrugsVincristine Sulfate·Doxorubicin Hydrochloride Liposome·BL-M08D1·Prednisone Acetate
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
204
Guangzhou, Suzhou
2026-09
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsPenpulimab·Methotrexate·Cytarabine·Rituximab
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
NCT07507318Diffuse Large B-Cell Lymphoma
DrugChidamide
Rong Tao
Phase 2
69
Shanghai
2026-06-16
Recruiting
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07368270Diffuse Large B Cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
DrugGlofitamab
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Not yet open
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07159906Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2
62
Hangzhou
2025-09-08
Recruiting
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650Diffuse Large B-Cell Lymphoma
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
NCT07070648Diffuse Large B-Cell Lymphoma, DLBCL
DrugPola-R-Chp
Fudan University
Observational
300
Shanghai
2025-05-09
Recruiting
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
NCT07001540Diffuse Large B-Cell Lymphoma
DrugPolatuzumab Vedotin
Fudan University
Phase 2
130
Shanghai
2025-05-08
Recruiting
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
NCT06929624Diffuse Large B-cell Lymphoma
DrugsGemcitabine Hydrochloride·Rituximab·Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
280
Beijing, Guangzhou
2025-04-24
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Ma’anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
NCT06803693Diffuse Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Decitabine·Zanubrutinib·Doxorubicin
Ruijin Hospital
Phase 2
152
Shanghai
2025-04-01
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06830031Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
Shanghai Exuma Biotechnology Ltd.
Phase 1
18
Tianjin
2025-03-25
Recruiting
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
NCT07188077Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Ting YANG
Observational
20
Fuzhou
2025-03-01
Recruiting
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
NCT07198230Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization
Ting YANG
Observational
10
Fuzhou
2025-03-01
Recruiting
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
NCT06764017Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Ningbo University
Phase 2
30
Ningbo
2025-02-01
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Recruiting
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
NCT06758037DLBCL, Diffuse Large B-Cell Lymphoma
DrugChidamide
First Affiliated Hospital of Ningbo University
Phase 2
50
Ningbo
2025-01-15
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039Diffuse Large B-Cell Lymphoma
DrugR-Chop
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
NCT07072208Diffuse Large B-Cell Lymphoma
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2024-11-01
Recruiting
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853Diffuse Large B-cell Lymphoma, Relapsed and Refractory
The First Affiliated Hospital of Xiamen University
Phase 2
22
Xiamen
2024-10-21
Recruiting
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
NCT06589089Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 2
18
Shanghai
2024-10-15
Recruiting
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411Diffuse Large B-cell Lymphoma
Navy General Hospital, Beijing
Phase 2
80
Beijing
2024-09-24
Recruiting
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263Diffuse Large B-cell Lymphoma
DrugZanubrutinib
Navy General Hospital, Beijing
Phase 2
240
Beijing
2024-08-30
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
DrugsR-CHOP Protocol·R-Chop·Selinexor
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
NCT06522555Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Phase 3
100
Shanghai
2024-07-29
Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06517004Diffuse Large B Cell Lymphoma
Fudan University
Phase 1
9
Shanghai
2024-07-18
Recruiting
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
NCT06213636Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell, Diffuse Large B Cell Lymphoma
Essen Biotech
Phase 1/2
75
Beijing
2024-07-10
Recruiting
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06594640Diffuse Large B-cell Lymphoma
DrugsMitoxantrone Hydrochloride Liposome·Prednisolone·Rituximab·Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
108
Tianjin
2024-05-30
Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
NCT06244368Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
115
Tianjin
2024-01-17
Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT06120166Diffuse Large B-cell Lymphoma
He Huang
Phase EARLY_PHASE1
18
Hangzhou
2023-11-16
Recruiting
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
NCT06176729Diffuse Large B Cell Lymphoma
Yan Zhang, MD
Phase 2
30
Beijing
2023-10-24
Recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910Diffuse Large B-Cell Lymphoma
DrugPolatuzumab Vedotin
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
Frontline of ASCT in High-risk DLBCL
NCT05831865Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Observational
175
Beijing
2023-05-03
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Recruiting
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628Diffuse Large B-cell Lymphoma
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Recruiting
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
NCT06005870Diffuse Large B Cell Lymphoma
DrugZanubrutinib
Huazhong University of Science and Technology
Phase 2
41
Wuhan
2022-11-26
Active, closed
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752Diffuse Large B-Cell Lymphoma
DrugEpcoritamab
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Recruiting
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
NCT05514327Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy, Bridging Therapy
Peking Union Medical College Hospital
Not applicable
20
Beijing
2022-09-01
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213Diffuse Large B Cell Lymphoma
DrugsTofacitinib·Decitabine·Zanubrutinib·Chidamide
Ruijin Hospital
Phase 2
76
Shanghai
2022-05-16
Recruiting
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
NCT05257018Diffuse Large B-cell Lymphoma
Fudan University
Phase 2
83
Shanghai, Ürümqi
2022-02-26
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
NCT06081478B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-01-18
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
DrugsRiabni·Ruxience·Granulocyte Colony-Stimulating Factor·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Recruiting
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT05018520Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 3
640
Shanghai
2021-09-17
Recruiting
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
NCT05040555Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
oubai, MD/PhD
Not applicable
64
Changchun
2021-08-30
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
NCT04460248Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 2
40
Shanghai
2020-08-26
By invitation
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
NCT04491721Diffuse Large B Cell Lymphoma
Chinese Academy of Medical Sciences
Observational
407
Beijing
2020-07
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies listing the condition Diffuse Large B Cell Lymphoma.

How many Diffuse Large B Cell Lymphoma trials are recruiting in China?

41 of the 54 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 8 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma), 54 studies
PhaseStudiesRecruitingShare
Phase 2171631.5%
Phase 310418.5%
Observational8714.8%
Phase 1/28514.8%
Phase 1549.3%
Not applicable437.4%
Phase 2/3111.9%
Phase EARLY_PHASE1111.9%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
Ruijin Hospital76
Fudan University44
Genmab30
Hoffmann-La Roche32
First Affiliated Hospital of Ningbo University22
Institute of Hematology & Blood Diseases Hospital, China22
Merck Sharp & Dohme LLC22
Navy General Hospital, Beijing22
Sichuan Baili Pharmaceutical Co., Ltd.20
Sun Yat-sen University22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.